Biogen's investigational drug salanersen received FDA Breakthrough Therapy Designation for treating spinal muscular atrophy (SMA), based on Phase 1b study results showing improved motor function and slowed neurodegeneration in children with suboptimal response to prior gene therapy. Salanersen, administered once yearly, offers potential high efficacy and is currently in Phase 3 trials targeting various SMA patient groups. This designation accelerates development and review, highlighting the urgent unmet needs in SMA treatment and Biogen's commitment to advancing new therapies.
Biogen announced that it will present 14 abstracts on its nephrology portfolio, including EMPAVELI (pegcetacoplan) and investigational felzartamab, at the 63rd European Renal Association Congress and the 2026 American Transplant Congress. The data co...
Pomerantz LLP is investigating Biogen Inc. for potential securities fraud following the company's announcement that its Phase 2 CELIA study for an Alzheimer's drug missed the primary endpoint. Despite Biogen calling the results "compelling," the stoc...
